| Oct 3 |
PGIM Jennison Health Sciences Fund Sold AbbVie (ABBV) in Q2. Here’s Why
|
| Oct 3 |
Investors in AbbVie (NYSE:ABBV) have seen impressive returns of 235% over the past five years
|
| Oct 3 |
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
|
| Oct 3 |
AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs
|
| Oct 2 |
AbbVie: $200 Peak (Rating Downgrade)
|
| Oct 2 |
AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation
|
| Oct 2 |
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
|
| Oct 2 |
5 Best Dividend Growth Stocks to Buy in October
|
| Oct 2 |
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
|
| Oct 2 |
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
|
